Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market

Wednesday, August 18, 2010 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

JERUSALEM and NEEDHAM, Massachusetts, August 18, 2010 Oridion (SIX Swiss Exchange: ORIDN), creator of theSmart Capnography(TM) family of algorithm-based solutions (IntegratedPulmonary Index(TM), SARA(TM), and Smart Breath Detection Algorithm(TM)),announced the signing of a new agreement with IMI Co. Ltd., a leadingdistributor of medical equipment in Japan. This agreement provides Oridionwith the opportunity to further expand into the Japanese market with its lineof Microstream(R) capnography monitoring products.

IMI will bundle sales of Capnostream(R)20 Smart Capnography monitorsincluding IPI* with their ventilators. This powerful combination will beoffered as SafetySet(TM), an innovative solution to improve patient safetyand make a clinical difference in patient care. IMI will begin selling theCapnostream(R)20 monitors and patented FilterLine(R) etCO2 sampling productsimmediately into the Critical Care environment and Home Care areas throughoutJapan.

Mr. Kazumasa Tsumuga, President of IMI, said: "We are happy to join withOridion to make available the best capnography technology to our hospitalmarkets in Japan. We believe the collaboration between IMI and Oridion willhelp improve the safety for all the patient populations in all clinicalsettings in Japan."

Gerry Feldman, President of Oridion Capnography Inc., remarks, "We arehonored to be working with IMI. The SafetySet package combining Capnostreamcapnography with ventilators sold by IMI is a pioneering strategy that willprovide added safety for patients in hospitals throughout Japan. Oridion iscommitted to improving the standard of healthcare worldwide and will continueto offer new ways to improve patient safety and make a clinical difference inpatient care."

*IPI helps caregivers manage complicated monitoring parameters with asingle, simple number. The IPI utilizes real time measures and interactionsof four parameters - exhaled carbon dioxide (etCO2), respiration rate, pulserate, and oxygenation (SpO2) - to provide a single indexed value, enablingclinicians to instantly assess the patient's respiratory status.

SARA (Smart Alarm Respiratory Analysis) is an alarm management algorithmthat, together with the Smart Breath Detection Algorithm, recognizes andreduces clinically insignificant alarms while accurately reflecting thepatient's condition and preserving caregiver alarm vigilance.

About Oridion

Oridion Systems Ltd. (http://www.oridion.com) is a global medical devicecompany specializing in patient safety monitoring. The Company operatesthrough wholly owned subsidiaries in the United States and Israel.

Oridion develops proprietary medical devices and patient interfaces,based on its patented Microstream(R) technologies, for the enhancement ofpatient safety through the monitoring of the carbon dioxide (CO2) in apatient's breath. These products provide effective, proven airway managementand are used in various clinical environments, including procedural sedation,pain management, critical care units, post-anesthesia care units, emergencymedical services, transport, alternate care and other settings wherepatients' ventilation may be compromised and at risk.

Certain statements made herein that are not historical areforward-looking. The words "estimate" "project" "intend" "expect" "believe"and similar expressions are intended to identify forward-looking statements.These forward-looking statements involve known and unknown risks anduncertainties. Many factors could cause the actual results, performance orachievements of the Company to be materially different from any futureresults, performance or achievements that may be expressed or implied by suchforward-looking statements, including, among others, our ability to maintainprofits, the market demands for our Capnography products, our ability tofocus our team on the Capnography business, changes in general economic andbusiness conditions, inability to maintain market acceptance to the Company'sproducts, inability to timely develop and introduce new technologies,products and applications, rapid changes in the market for the Company'sproducts, loss of market share and pressure on prices resulting fromcompetition, introduction of competing products by other companies, inabilityto manage growth and expansion, loss of key OEM partners, inability toattract and retain qualified personnel, inability to protect the Company'sproprietary technology. The Company does not assure any obligation to updatethe forward-looking information contained in this press release.For further Oridion information please contact: Alan Adler, Chairman and Chief Executive Officer Walter Tabachnik, Chief Financial Officer Elena Gerberg, Investor Relations e-mail: info@oridion.com website: http://www.oridion.com phone: +972-2-589-9159 address: Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

SOURCE Oridion Systems Ltd.

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store